Status: Not yet recruiting
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia.
This is a phase 2 study designed to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.
Participants needed: 4
Trial details
Phase: Phase 2Age: 18-79Biological sex: MaleType: InterventionalSponsor: Kiminori Kimura, MDUpdated: Jul 2, 2026Locations: 3
Eligibility criteria
Patients who are serum HIV-RNA positive or HIV antibody positive, with HIV-RNA m... [+5]
Patients with liver cirrhosis caused by etiologies other than HCV or of unknown... [+4]